Ekimas Corp (ASNB) SEC Filing 10-K Annual Report for the fiscal year ending Thursday, March 31, 2022

SEC Filings

ASNB Annual Reports

Advansource Biomaterials Corp

CIK: 1499961 Ticker: ASNB
Cover - USD ($)
12 Months Ended
Mar. 31, 2022
Jun. 28, 2022
Sep. 30, 2021
Cover [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Annual Reporttrue  
Document Transition Reportfalse  
Document Period End DateMar. 31, 2022  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2022  
Current Fiscal Year End Date--03-31  
Entity File Number0-28034  
Entity Registrant NameEKIMAS Corporation  
Entity Central Index Key0001011060  
Entity Tax Identification Number04-3186647  
Entity Incorporation, State or Country CodeDE  
Entity Address, Address Line One3651 Lindell Road  
Entity Address, Address Line TwoSuite D565  
Entity Address, City or TownLas Vegas  
Entity Address, State or ProvinceNV  
Entity Address, Postal Zip Code89103  
City Area Code(424)  
Local Phone Number256-8560  
Title of 12(g) SecurityCommon Stock, $.001 par value per share  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusNo  
Entity Interactive Data CurrentNo  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companytrue  
Entity Public Float  $ 1,056,000
Entity Common Stock, Shares Outstanding 5,681,248 
Auditor Firm ID287  
Auditor NameLiggett & Webb, P.A  
Auditor LocationBoynton Beach, Florida  

View differences made from one year to another to evaluate Advansource Biomaterials Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Advansource Biomaterials Corp.


Assess how Advansource Biomaterials Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Advansource Biomaterials Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Advansource Biomaterials Corp provided additional information to their SEC Filing as exhibits

Ticker: ASNB
CIK: 1011060
Form Type: 10-K Annual Report
Accession Number: 0001493152-22-017952
Submitted to the SEC: Tue Jun 28 2022 3:41:01 PM EST
Accepted by the SEC: Tue Jun 28 2022
Period: Thursday, March 31, 2022
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: